EGFR

Mutations in the protein epiregulin, an EGF receptor ligand, affect larger epithelial cell reorganization and may contribute to early cancer development, Vanderbilt researchers discovered.

Combining two drugs reduced colorectal cancer cell growth in vitro and in an animal model, suggesting the combination may be a promising treatment for patients.

A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently.

A group of Vanderbilt students, residents and faculty — connected through their passion for health equity — have identified and worked together to rectify longstanding concerns about the inappropriate use of race as a variable in the calculation of estimated glomerular filtration rate (eGFR), which estimates a patient’s level of kidney function and helps determine the stage of kidney disease.

Men are more susceptible to progressive kidney disease than women; new VUMC studies point to differences in the expression and activation of the EGF receptor.

Pathways activated by the epidermal growth factor receptor may be attractive targets to treat diabetic kidney disease, according to new findings from Vanderbilt investigators.

Activation of the signaling protein YAP may be a target for treating acute kidney injury, which affects up to 20 percent of hospitalized patients.